Clinical Trials at HOAF
At Hematology Oncology Associates of Fredericksburg, we are committed to offering our patients the most advanced comprehensive cancer care. Clinical trials are an integral part of this treatment package, as they offer access to new treatments not yet available outside of the trial. We currently have multiple trials open for enrollment. In addition, we are a research affiliate with VCU Massey Cancer Center in Richmond, Virginia. This affiliation allows our patients to access leading-edge clinical trials while receiving treatment in Fredericksburg.
We encourage you to discuss your options with your provider.
The following studies are active:
Protocol I3Y-MC-JPCF: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Objective: To evaluate the efficacy, in terms of IDFS, for patients with HR+, HER2- early stage breast cancer for abemaciclib plus adjuvant endocrine therapy versus adjuvant endocrine therapy alone
A Phase III, Open-Label, Randomized Study to Investigate The Efficacy and Safety of Atezolizumab (Anti−Pd-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients With Completely Resected Stage IB−IIIA Non−Small Cell Lung Cancer
Objective: To evaluate the efficacy of sixteen cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator
Randomized Phase III Trial Evaluating The Role of Weight Loss In Adjuvant Treatment of Overweight And Obese Women With Early Breast Cancer
Objective: To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival in overweight and obese women diagnosed with HER-2 negative, stage II and III breast cancer.
An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Objective: Describe tolerability and treatment safety of a Carfilzomib/Dexamethasone (Kd) regimen twice weekly for cycles 1-6 followed by Kd once weekly for cycles 7-12 in subjects with relapsed or refractory multiple myeloma with 1-3 prior lines of therapy at study entry.
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
Objective: To compare the effect of R-CHOP/plus enzastaurin versus R-CHOP on OS in treatment naïve, high-risk subjects with DLBCL who possess the DGM1™ biomarker.
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Objective: To compare the efficacy of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic pancreatic cancer as measured by OS.
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Objective: To compare the event-free survival (EFS) by blinded independent central review (BICR) in participants receiving nivolumab plus platinum doublet chemotherapy vs participants receiving platinum doublet chemotherapy in operable stage IB ( 4 cm), II, or resectable IIIA (N2) NSCLC.